12:00 AM
 | 
Jul 15, 2016
 |  BC Extra  |  Clinical News

Ziopharm slides on news of patient deaths

Ziopharm Oncology Inc. (NASDAQ:ZIOP) lost $0.66 (12%) to $5.01 on Friday after it reported three patient deaths in a Phase I study of Ad-RTS-hIL-12 to treat recurrent or progressive glioblastoma multiforme (GBM) or grade III malignant glioma.

The company said one death due to intracranial hemorrhage...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >